Free Trial
NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Avenue Therapeutics logo
$0.36 +0.11 (+44.84%)
As of 07/11/2025 03:55 PM Eastern

About Avenue Therapeutics Stock (NASDAQ:ATXI)

Key Stats

Today's Range
$0.25
$0.40
50-Day Range
$0.18
$0.37
52-Week Range
$0.17
$3.93
Volume
32,282 shs
Average Volume
130,389 shs
Market Capitalization
$1.16 million
P/E Ratio
0.02
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avenue Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

ATXI MarketRank™: 

Avenue Therapeutics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Avenue Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avenue Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.90.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avenue Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.96.

  • Price to Book Value per Share Ratio

    Avenue Therapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avenue Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.48% of the float of Avenue Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving.
  • Dividend Yield

    Avenue Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Avenue Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.48% of the float of Avenue Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving.
  • News Sentiment

    Avenue Therapeutics has a news sentiment score of -0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Avenue Therapeutics this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

  • Read more about Avenue Therapeutics' insider trading history.
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

ATXI Stock Analysis - Frequently Asked Questions

Avenue Therapeutics' stock was trading at $2.00 at the beginning of the year. Since then, ATXI stock has decreased by 81.8% and is now trading at $0.3650.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its quarterly earnings data on Friday, August, 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $5.38.

Shares of Avenue Therapeutics reverse split on Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Avenue Therapeutics (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at a price of $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/09/2024
Today
7/12/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATXI
CIK
1644963
Fax
N/A
Employees
4
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($7.49)
Trailing P/E Ratio
0.02
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.38 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-471.57%
Return on Assets
-296.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.70
Quick Ratio
2.70

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.92 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
3,183,000
Free Float
2,017,000
Market Cap
$1.16 million
Optionable
Not Optionable
Beta
-0.08

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ATXI) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners